Keywords: Molecular Imaging, CancerPDAC is a highly aggressive malignant cancer and the 3rd leading cause of cancer related deaths in the US. The aggressive nature of PDAC is in part due to the desmoplastic tumor microenvironment, which promotes rapid tumor growth and impedes therapeutic efficacy of conventional therapies. Immune checkpoint inhibitors have showed specific efficacy in PDAC promotes extracellular remodeling for effective treatment of aggressive tumors. In this study we investigated the ability of an MR molecular imaging technology for image guidance and therapeutic monitoring of PD-L1 treated PDAC tumors.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords